Treatment of neurodegenerative disease with sodium chlorite
View Patent ↗The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
1. A method of treating a dementia in a subject in need thereof, the method comprising:
a) determining that the subject has a plasma level of C-reactive protein that is at least 1125 ng/mL; and
b) based on the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL, administering to the subject an amount of sodium chlorite that is therapeutically-effective for the dementia,
wherein the subject is under age 65.
2. The method of claim 1 , wherein the administering is parenteral.
3. The method of claim 1 , wherein the administering is intravenous.
4. The method of claim 1 , wherein the administering occurs over a period ranging from about 0.5 to about 4 hours.
5. The method of claim 1 , wherein the administering occurs at least once per month for a period of at least a year.
6. The method of claim 1 , wherein the administering occurs at least once per week for a period of at least one month.
7. The method of claim 1 , wherein the sodium chlorite is administered in an amount ranging from 0.1 to 10 mg/kg by body weight.
8. The method of claim 1 , wherein the sodium chlorite is administered in an amount ranging from 1 to 2 mg/kg by body weight.
9. The method of claim 1 , wherein the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL comprises detecting the C-reactive protein in a biological sample of the subject.
10. The method of claim 1 , wherein the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL comprises quantifying the C-reactive protein in a biological sample of the subject.
11. The method of claim 1 , wherein the dementia is Amyotrophic Lateral Sclerosis (ALS).
12. The method of claim 1 , wherein the subject exhibits a behavioral symptom of the dementia.
13. The method of claim 1 , wherein the subject exhibits a physical symptom of the dementia.
14. The method of claim 1 , wherein the subject is human.